CLSD Clearside Biomedical Inc

Clearside Biomedical to Present at the Cowen and Company 39th Annual Health Care Conference

Clearside Biomedical to Present at the Cowen and Company 39th Annual Health Care Conference

ALPHARETTA, Ga., March 04, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Daniel H. White, President and Chief Executive Officer, will present a company overview at the Cowen and Company 39th Annual Health Care Conference in Boston on Wednesday, March 13, 2019 at 8:00 a.m. ET.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: . An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases. Clearside’s proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company’s unique platform for eye disease treatments is inherently flexible and intended to work with established medicines, new formulations of medicines, as well as future innovations such as gene therapy. Clearside is headquartered in Alpharetta, GA. For more information, please visit .

Investor and Media Contacts:



Jenny Kobin (919) 423-4799

Remy Bernarda (415) 203-6386

Source: Clearside Biomedical, Inc.

EN
04/03/2019

Underlying

CLSDClearside Biomedical Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clearside Biomedical Inc

 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical to Pursue Strategic Sale of its Business Through ...

Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential - - CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy - - IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema - ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -...

November 24, 2025 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical Announces Multiple Presentations on Suprachoroida...

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress - Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad - ALPHARETTA, Ga., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the...

August 26, 2025 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Trea...

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has...

July 23, 2025 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical Announces Plan to Explore Strategic Alternatives ...

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations - ALPHARETTA, G...

July 17, 2025 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical Announces Multiple Presentations to be Featured a...

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), a...

June 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch